To hear about similar clinical trials, please enter your email below
Trial Title:
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
NCT ID:
NCT05491928
Condition:
Metastatic Cancer
Conditions: Official terms:
Neoplasm Metastasis
Tempol
Study type:
Expanded Access
Overall status:
Available
Intervention:
Intervention type:
Drug
Intervention name:
Tempol
Description:
Tempol will be given as an adjunct to chemotherapy.
Other name:
MBM-0-1 MBM-02
Summary:
The objective is to provide terminally diagnosed patients with a last line of treatment
while improving overall quality of life. Tempol can be added to any chemotherapy regimen
to potentially reduce side effects and overcome chemoresistance.
Detailed description:
The objective is to provide terminally diagnosed patients assigned to palliative care and
palliative chemotherapy a last line treatment with Tempol. In vivo studies have shown
Tempol to work synergistically with a number of chemotherapy agents increasing treatment
response and reducing chemoresistance. Additionally, Tempol has been shown to provide
protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing
side effects. Tempol inhibits HIF-1/VEGF among others in cancerous cells while
upregulating GSH/NrF2 among others in non-cancerous cells.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- metastatic terminally diagnosed cancer
Exclusion Criteria:
-
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
UCHealth University of Colorado Cancer Center - Anschutz Medical Campus
Address:
City:
Aurora
Zip:
80045
Country:
United States
Status:
Available
Lead sponsor:
Agency:
Matrix Biomed, Inc.
Agency class:
Industry
Source:
Matrix Biomed, Inc.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05491928
